التفاصيل البيبلوغرافية
| العنوان: |
Outcomes and factors associated with relapse of vaccine-induced liver injury after SARS CoV-2 immunization: A nationwide study. |
| المؤلفون: |
Barreira-Díaz, Ana, Riveiro-Barciela, Mar, Fernández-Bonilla, Eva María, Bernal, Vanesa, Castiella, Agustín, Casado-Martín, Marta, Delgado, Carolina, Londoño, María-Carlota, Díaz-González, Álvaro, Pérez-Medrano, Indhira, Conthe, Andrés, Sala, Margarita, Mateos, Beatriz, Gómez-Camarero, Judith, Antón-Conejero, Dolores, Pozo-Calzada, Carmen Del, Cuenca, Francisca, Villagrasa-Vilella, Ares, Salcedo, Magdalena |
| المصدر: |
Annals of Hepatology: Official Journal of the Mexican Association of Hepatology; May/Jun2024, Vol. 29 Issue 3, p1-6, 6p |
| مصطلحات موضوعية: |
SARS-CoV-2, LIVER injuries, AUTOIMMUNE hepatitis, IMMUNIZATION, LIVER biopsy, CHOLANGITIS |
| مستخلص: |
Introduction and Objectives: Different patterns of liver injury have been reported in association with the SARSCoV-2 vaccines. The aim of this study was to describe a nationwide cohort of patients with SARS CoV-2 vaccine-induced liver injury, focusing on treatment and the evolution after further booster administration. Patients and Methods: multicentre, retrospective-prospective study, including subjects who developed abnormal liver tests within 90 days after administration of SARS-CoV-2 vaccination. Results: 47 cases were collected: 17 after prime dose and 30 after booster. Age was 57 years, 30 (63.8 %) were female, and 7 (14.9 %) had a history of prior autoimmune hepatitis (AIH). Most cases were non-severe, though 9 (19.1 %) developed acute liver injury or failure (ALF). Liver injury tended to be more severe in those presenting after a booster (p=0.084). Pattern of liver injury was hepatocellular (80.9 %), mixed (12.8 %) and 3 (6.4 %) cholestatic. Liver biopsy was performed on 33 patients; 29 showed findings of AIH. Forty-one (87.2 %) patients received immunosuppressants, mostly corticosteroids (35/41). One required liver transplantation and another died due to ALF. Immunosuppression was discontinued in 6/41 patients without later rebound. Twenty-five subjects received at least one booster and 7 (28.0 %) relapsed from the liver injury, but all were non-severe. Recurrence was less frequent among patients on immunosuppressants at booster administration (28.6 % vs. 88.9 %, p=0.007). Conclusions: SARS CoV-2 vaccine-induced liver injury is heterogeneous but mostly immune-mediated. Relapse of liver injury after re-exposure to vaccine is frequent (28.0 %) but mild. Immunosuppression at booster administration is associated with a lower risk of liver injury. [ABSTRACT FROM AUTHOR] |
|
Copyright of Annals of Hepatology: Official Journal of the Mexican Association of Hepatology is the property of Fundacion Clinica Medica Sur and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| قاعدة البيانات: |
Complementary Index |
Full Text Finder